Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.


30 Sep 2019


Poster Display session 3



Tumour Site


Jianzhen Lin


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


J. Lin1, X. Yang1, S. Zhao2, J. Long3, J. Pan4, K. Hu5, L. Zhao6, L. Huo7, X. Sang3, K. Wang2, H. Zhao3

Author affiliations

  • 1 Liver Surgery, Peking Union Medical College Hospital, 100730 - Beijing/CN
  • 2 Bioinformatics, OrigiMed, 200135 - Shanghai/CN
  • 3 Liver Surgery, PUMCH-Peking Union Medical College Hospital (East), 100730 - Beijing/CN
  • 4 Radiology, PUMCH-Peking Union Medical College Hospital (East), 100730 - Beijing/CN
  • 5 Radiotherapy, PUMCH-Peking Union Medical College Hospital (East), 100730 - Beijing/CN
  • 6 Oncology, PUMCH-Peking Union Medical College Hospital (East), 100730 - Beijing/CN
  • 7 Nuclear Medicine, PUMCH-Peking Union Medical College Hospital (East), 100730 - Beijing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2421


Co-inhibiting angiogenesis and PD-1/PD-L1 is a promising regimen for several solid tumours; however, its role in bile tract carcinoma (BTC) remains unclear. We sought to investigate the antitumour efficacy and toxicity of lenvatinib (an oral anti-angiogenesis drug) plus PD-1 blockade in patients with advanced BTC.


A retrospective cohort study involved patients with advanced BTC who have treated with lenvatinib plus PD-1 blockade. The PD-1 inhibitors only included pembrolizumab and nivolumab. The primary outcomes of this study were the objective response rate (ORR) and progression-free survival (PFS). Biomarkers, including PD-L1 expression, tumour mutational burden (TMB) and genetic alterations, were analysed.


In total, 56 patients (29 with lenvatinib plus nivolumab, 27 with lenvatinib plus pembrolizumab) were enrolled. The ORR was 30.4%, the disease control rate was 85.7%, and the clinical benefit rate was 50%. The median PFS was 5.0 months (95% CI: 4.0-6.0), and the median overall survival was 11.0 months (95% CI: 6.6-15.4). For tolerability, 96.4% of the patients had adverse events (AEs), but only 19.6% of the patients experienced grade-3 AEs without grade-4/5 AEs occurring. Fatigue, hypertension and hypothyroidism were the most common AEs. Moreover, PD-L1 positive expression had higher ORR and longer PFS, while TMB was not correlated with the response and survival outcomes. Further analysis of efficacy-related factors demonstrated that patients with resected BTC could obtain longer OS.


Lenvatinib plus PD-1 inhibitor presents an effective and safe strategy in patients with advanced BTC, especially those with PD-L1 positive expression and prior surgical resection.

Clinical trial identification


Editorial acknowledgement

Milind Javle.

Legal entity responsible for the study

The protocol of this study was compliant with the principles of the Declaration of Helsinki and was also approved by the institutional review board and ethics committee of PUMCH.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.